Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Other Non-Current Assets (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Other Non-Current Assets for 7 consecutive years, with $18.4 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 6704.81% to $18.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.4 million through Dec 2025, up 6704.81% year-over-year, with the annual reading at $18.4 million for FY2025, 6704.81% up from the prior year.
  • Other Non-Current Assets hit $18.4 million in Q4 2025 for Harmony Biosciences Holdings, up from $9.7 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $18.4 million in Q4 2025 to a low of $152000.0 in Q1 2021.
  • Historically, Other Non-Current Assets has averaged $3.5 million across 5 years, with a median of $1.6 million in 2021.
  • Biggest five-year swings in Other Non-Current Assets: plummeted 90.48% in 2024 and later soared 6704.81% in 2025.
  • Year by year, Other Non-Current Assets stood at $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then crashed by 64.0% to $270000.0 in 2023, then changed by 0.0% to $270000.0 in 2024, then skyrocketed by 6704.81% to $18.4 million in 2025.
  • Business Quant data shows Other Non-Current Assets for HRMY at $18.4 million in Q4 2025, $9.7 million in Q3 2025, and $5.5 million in Q2 2025.